-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the centralized procurement of generic drugs and the inclusion of innovative drugs in the new medical insurance, the domestic pharmaceutical market is shifting to an innovation-driven market
.
In recent years, pharmaceutical companies have placed more emphasis on innovative drugs, and with the continuous increase in R&D investment, the approval of domestically-made innovative drugs has also shown a blowout trend
.
From the perspective of domestic pharmaceutical companies, investment in innovative R&D continues to rise
.
Statistics show that R&D investment of large-scale enterprises has increased by about 8% annually.
In 2020, R&D expenses of listed companies will account for more than 6% of sales revenue
.
In addition, data shows that the R&D investment of innovative drug industry chain companies in the third quarter of 2021 increased by more than 30% year-on-year, reaching 20.
996 billion yuan
.
Among them, Hengrui Pharmaceuticals R&D investment reached 4.
142 billion yuan, accounting for 20.
51% of revenue; Fosun Pharma’s R&D investment was 2.
414 billion yuan, accounting for 8.
92% of revenue
.
For example, under the high R&D investment, Hengrui Medicine has submitted a total of 31 clinical trial applications in the first three quarters of this year, and has obtained 23 approvals
.
In the first half of 2021, 5 new drug applications have been approved, which is close to the number of approvals for the entire year of 2020
.
According to the industry, it is a common feature of biomedical companies to attach importance to R&D investment
.
For example, for the pharmaceutical companies that have landed on the Science and Technology Innovation Board this year, the prospectus of Dizhe Pharmaceuticals shows that in 2018-2020, the company's research and development expenses were 210 million yuan, 421 million yuan, and 439 million yuan, respectively, accounting for 533.
25% and 1027.
45 of revenue.
%, 1583.
15%
.
In the first half of 2021, the company's research and development expenses reached 258 million yuan, accounting for 8314.
78% of revenue
.
The relevant data of Novozan, a pharmaceutical company listed on November 15 this year, also shows that from 2018 to 2020, the company's research and development expenses were 5,304,500 yuan, 62,296,600 yuan, and 125,533,400 yuan, accounting for 31.
03% and 23.
21.
%, 8.
02%
.
In the first half of 2021, the company’s R&D expenses were RMB 84,517,300, accounting for 10.
24% of revenue
.
In addition, public data shows that in the R&D investment of domestic pharmaceutical companies in 2021H1, BeiGene invested a total of 4.
378 billion yuan, a simultaneous increase of 15%; CSPC’s R&D investment was 16.
13, an increase of 11% year-on-year
.
According to the industry, innovation and R&D are the engine and core competitiveness for BeiGene's long-term development, and are also the focus of the company's continuous investment
.
The company's core drugs include 3 self-developed drugs Baiyueze, Baizean and Baihuize that have been marketed
.
Among them, Baiyueze is an anti-cancer drug independently developed by China that has been approved by the US FDA and certified as a breakthrough therapy
.
It is reported that in the field of innovative drugs, Rongchang Bio, as the leader of new antibody drugs in China, has also attracted market attention
.
Rongchang Biologics develops new antibody drugs on three platforms: antibody fusion protein, ADC (antibody-coupled drugs), and double antibodies
.
There are currently two main products in the pipeline: BlyS/APRIL dual-target fusion protein-Taltazep, which has achieved a breakthrough in the treatment of systemic lupus erythematosus.
At the same time, it is developing research on various autoimmune diseases such as IgA nephropathy and Sjogren’s disease; China’s self-developed ADC-Vicituzumab is also a domestic ADC that has been granted breakthrough therapy certification by the US FDA.
Its indications for gastric cancer are China was approved for listing, and urothelial cancer was approved by the FDA as a breakthrough therapy
.
In recent years, with the advancement of sound pharmaceutical policies, the country has ushered in a big trend of innovation, but the development of innovative drugs is still facing many difficulties
.
Some analysts said that the research and development of new drugs needs to focus on clinical needs as the center, clinical value as the orientation, and focus on precise treatment drive; strengthen basic research, strengthen cognition of diseases, and improve drug innovation capabilities; reasonable selection of fast channels and attention The management of the whole life cycle, pay attention to the new methods of old drugs
.
In addition, the current cooperative development between companies is also considered to be another way for pharmaceutical companies to innovate
.
.
In recent years, pharmaceutical companies have placed more emphasis on innovative drugs, and with the continuous increase in R&D investment, the approval of domestically-made innovative drugs has also shown a blowout trend
.
From the perspective of domestic pharmaceutical companies, investment in innovative R&D continues to rise
.
Statistics show that R&D investment of large-scale enterprises has increased by about 8% annually.
In 2020, R&D expenses of listed companies will account for more than 6% of sales revenue
.
In addition, data shows that the R&D investment of innovative drug industry chain companies in the third quarter of 2021 increased by more than 30% year-on-year, reaching 20.
996 billion yuan
.
Among them, Hengrui Pharmaceuticals R&D investment reached 4.
142 billion yuan, accounting for 20.
51% of revenue; Fosun Pharma’s R&D investment was 2.
414 billion yuan, accounting for 8.
92% of revenue
.
For example, under the high R&D investment, Hengrui Medicine has submitted a total of 31 clinical trial applications in the first three quarters of this year, and has obtained 23 approvals
.
In the first half of 2021, 5 new drug applications have been approved, which is close to the number of approvals for the entire year of 2020
.
According to the industry, it is a common feature of biomedical companies to attach importance to R&D investment
.
For example, for the pharmaceutical companies that have landed on the Science and Technology Innovation Board this year, the prospectus of Dizhe Pharmaceuticals shows that in 2018-2020, the company's research and development expenses were 210 million yuan, 421 million yuan, and 439 million yuan, respectively, accounting for 533.
25% and 1027.
45 of revenue.
%, 1583.
15%
.
In the first half of 2021, the company's research and development expenses reached 258 million yuan, accounting for 8314.
78% of revenue
.
The relevant data of Novozan, a pharmaceutical company listed on November 15 this year, also shows that from 2018 to 2020, the company's research and development expenses were 5,304,500 yuan, 62,296,600 yuan, and 125,533,400 yuan, accounting for 31.
03% and 23.
21.
%, 8.
02%
.
In the first half of 2021, the company’s R&D expenses were RMB 84,517,300, accounting for 10.
24% of revenue
.
In addition, public data shows that in the R&D investment of domestic pharmaceutical companies in 2021H1, BeiGene invested a total of 4.
378 billion yuan, a simultaneous increase of 15%; CSPC’s R&D investment was 16.
13, an increase of 11% year-on-year
.
According to the industry, innovation and R&D are the engine and core competitiveness for BeiGene's long-term development, and are also the focus of the company's continuous investment
.
The company's core drugs include 3 self-developed drugs Baiyueze, Baizean and Baihuize that have been marketed
.
Among them, Baiyueze is an anti-cancer drug independently developed by China that has been approved by the US FDA and certified as a breakthrough therapy
.
It is reported that in the field of innovative drugs, Rongchang Bio, as the leader of new antibody drugs in China, has also attracted market attention
.
Rongchang Biologics develops new antibody drugs on three platforms: antibody fusion protein, ADC (antibody-coupled drugs), and double antibodies
.
There are currently two main products in the pipeline: BlyS/APRIL dual-target fusion protein-Taltazep, which has achieved a breakthrough in the treatment of systemic lupus erythematosus.
At the same time, it is developing research on various autoimmune diseases such as IgA nephropathy and Sjogren’s disease; China’s self-developed ADC-Vicituzumab is also a domestic ADC that has been granted breakthrough therapy certification by the US FDA.
Its indications for gastric cancer are China was approved for listing, and urothelial cancer was approved by the FDA as a breakthrough therapy
.
In recent years, with the advancement of sound pharmaceutical policies, the country has ushered in a big trend of innovation, but the development of innovative drugs is still facing many difficulties
.
Some analysts said that the research and development of new drugs needs to focus on clinical needs as the center, clinical value as the orientation, and focus on precise treatment drive; strengthen basic research, strengthen cognition of diseases, and improve drug innovation capabilities; reasonable selection of fast channels and attention The management of the whole life cycle, pay attention to the new methods of old drugs
.
In addition, the current cooperative development between companies is also considered to be another way for pharmaceutical companies to innovate
.
